Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and NORTH TANDRIDGE PCN

Document Number GB-74428

Date of Preparation Feb 2026

Project title	Establishing Quality Improvement through Partnership
Aims and Objectives	1. Support HCPs with their understanding of NG28 guidelines and effective treatment for people living with type 2 diabetes mellitus. 2. Identify at risk patients aligned to NG28 guidelines through the implementation of a clinical search. 3. Provide capacity support, in partnership with the NHS, to review high risk patients. 4. Embed high quality type 2 diabetes care through implementation of a NG28 clinical template. 5. Provide a framework for evidence capture and CQC audit readiness.
Anticipated benefits	Patient benefits: • Potentially better controlled type 2 diabetes patients living with type 2 diabetes disease by having medicines optimised to NG28 guidelines• Access to medicines review in a more timely manner complications and offer faster access to evidence based medicines. •Potential for reduced healthcare system costs including unplanned avoidable cardiovascular events in people with type 2 diabetes. •Upskilling of Primary Care clinical workforce prioritised for delivering type 2 diabetes patient medicine optimisation. •The inclusion of a NG28 clinical template produced and funded by AZ that will support the ongoing consistency of medicine reviews per NG28 guidelines. NHS benefits: •To optimise and prioritise care for patients by case finding management of NICE NG28 guideline, for people with type 2 diabetes at the highest risk of cardiovascular and renal. AZ benefits: •Demonstrates partnership working with the NHS •Allows AZ to focus on a specific area of unmet need •Potential increase of cardiovascular, renal and metabolic medicines prescribing if clinically appropriate for patients, which may include AZ products. The project is not reliant on prescribing AZ medicines and the

	decision to prescribe will remain with the clinician in line with NG28 guidelines.
Timeline	The project will commence 1-Dec-2025 and will continue for 12months.
Contributions	The project will include the pooling of skills, experience and resources from both parties. AstraZeneca will provide funding for additional clinical time, and AZ employee time for project management and evaluation at a total cost of £18,215.31 The NHS is contributing clinical time and project analysis at a total cost of £12,143.54. The NHS contribution does not include transfer of monies; it is based on cost of resource allocation. Full details of contributions are included in the agreed Joint working agreement with the NHS.